课题基金 / 基金详情

Remote stroke diagnosis and treatment platform (RESDAT)

Remote stroke diagnosis and treatment platform (RESDAT)
远程脑卒中诊疗平台(RESDAT)
批准号:
10079373
负责人:
金额:
$50.81万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2024
资助国家:
英国
项目状态:
未结题
起止时间:
2024 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
中风是全球严重长期残疾的主要原因,中风的快速诊断和治疗对于改善中风的结局至关重要。中风是英国第四大死亡原因,每年花费256亿英镑。最常见的中风类型是大血管闭塞,这是一个凝块停留在大脑的主要动脉。多项临床研究表明,采用机械血栓切除术治疗的患者结局最佳。血栓切除术是一种医疗程序,专业医生通过在腹股沟或手臂上做一个小切口,并使用导管(薄的柔性管)引导器械通过体内血管到达大脑中的血栓进行清除,从而从阻塞的动脉中清除血栓。然而,机械血栓切除术对患者和临床医生来说仍然存在许多风险。对于患者来说,存在血管损伤的风险。为了解决这些问题,我们希望创建一个机器人系统,可以提高血栓切除术的准确性,可用性和安全性。该系统将提供以下好处:更准确的凝块清除:** 机器人可以编程为比人手更精确地移动,这有助于确保完全清除凝块,并有助于降低手术过程中造成损害的风险。** 血栓切除术将不需要训练有素的操作员亲自在场,这意味着在任何时候都可以更容易和更具成本效益地进入偏远地区。更少的辐射暴露:** 临床医生在进行这些需要定期进行以挽救生命的手术时,会暴露在高于正常水平的辐射中。通过这个项目,英国和欧洲领先的中风AI公司Brainomix和苏黎世联邦理工学院(ETH)的机器人子公司Nanoflex将合作开发一个新的平台,能够微妙地引导更有效的设备通过血栓。
英文摘要
Rapid diagnosis and treatment of stroke is critical in improving outcomes for stroke, which is the leading cause of serious long-term disability globally. Stroke is the fourth largest cause of death in the UK and costs £25.6 billion annually.The most common type of stroke is a large vessel occlusion which is a clot lodged in a major artery in the brain. Multiple clinical studies to have shown that patients have the best outcomes when treated with mechanical thrombectomy. Thrombectomy is a medical procedure where a specialist physician removes a blood clot from a blocked artery by making a small incision in the groin or arm, and using a catheter (thin, flexible tube) to guide a device through blood vessels in the body to the clot in the brain for removal.However, there are still many risks involved in mechanical thrombectomy for the patient and the clinicians. For the patient, there are risks of injury to the blood vessels. To address these problems, we want to create a robotic system that can improve the accuracy, availability, and safety of thrombectomy. The system will provide the following benefits:\***More accurate clot removal:** Robots can be programmed to move with more precision than human hands, which can help to ensure that the clot is removed completely and can help to reduce the risk of damage that is caused during the procedure.\***Widen access to underserved populations:** Thrombectomies will not require the physical presence of a highly trained operator meaning that it will be easier and more cost-effective to enable access in remote areas at any time.\***Less exposure to radiation:** Clinicians are exposed to higher than normal levels of radiation to carry out these procedures that need to be carried out regularly to save lives.Through this project, Brainomix, the leading stroke AI company in the UK & Europe, and Nanoflex, a robotics spin-off from ETH Zurich, will partner to develop a novel platform to be able to delicately guide more effective devices through to clots.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
  • 批准号:
    82371332
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    胡琴
  • 依托单位:
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    万杰清
  • 依托单位:
KLK10调控胶质—血管耦合与对话促缺血性卒中后血脑屏障修复的机制
  • 批准号:
    82371465
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李龙宣
  • 依托单位:
基于仿生矿化法构建氢离子捕获的炎症调节性水凝胶微球在卒中治疗中的研究
  • 批准号:
    82372120
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    阮慧瞳
  • 依托单位: